HIV lipodystrophy: Risk factors, pathogenesis, diagnosis and management

AIDS

Volumn 17, Issue SUPPL. 1, 2003, Pages

  Carr, Andrew ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Complications; HIV; Lactate; Lipdystrophy; Lipids

Indexed keywords

ABACAVIR; ANTIDIABETIC AGENT; ANTIRETROVIRUS AGENT; ATORVASTATIN; C PEPTIDE; CD4 ANTIGEN; EFAVIRENZ; GEMFIBROZIL; GLUCOSE TRANSPORTER 4; GROWTH HORMONE; INDINAVIR; LEPTIN; METFORMIN; MITOCHONDRIAL DNA; NEVIRAPINE; NUCLEOSIDE ANALOG; PRAVASTATIN; PROTEASOME; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; SAQUINAVIR; SIMVASTATIN; SOMATOMEDIN C; STAVUDINE; STEROL REGULATORY ELEMENT BINDING PROTEIN; TESTOSTERONE; TRIACYLGLYCEROL; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADIPOCYTE; AGE; ATHEROSCLEROSIS; BODY FAT; BODY WEIGHT; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CLINICAL FEATURE; CLINICAL TRIAL; CYTOTOXICITY; DISEASE EXACERBATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; EXERCISE; GROWTH HORMONE BLOOD LEVEL; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LACTIC ACIDEMIA; LIPID BLOOD LEVEL; LIPID STORAGE; LIPIDOSIS; LIPOATROPHY; LIPODYSTROPHY; LIPOGENESIS; LIPOLYSIS; LIVER CELL; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PHYSICAL EXAMINATION; PLASTIC SURGERY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVIEW; RISK FACTOR; SEX DIFFERENCE; SOCIAL ASPECT; STEM CELL; SUBSTITUTION THERAPY; T LYMPHOCYTE; TESTOSTERONE BLOOD LEVEL; VIRUS REPLICATION; WASTING SYNDROME;

EID: 0038204340     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200304001-00017     Document Type: Review

References (81)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
2. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998, 12:F37-F39.
3. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998, 351:871-875.
4. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. 'Buffalo hump' in men with HIV-1 infection. Lancet 1998, 351:867-870.
5. Hengel RL, Watts NB, Lennox JL. Multiple symmetrical lipomatosis associated with protease inhibitors. Lancet 1997, 350:1596. [Letter]
6. Roth VR, Kravcik S, Angel JB. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 1998, 27:65-67.
7. Gervasoni C, Ridolfo AL, Trifirò G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999, 13:465-472.
8. Falutz J, Turcot D. Considerations in the development of a case definition for HIV/HAART-associated lipodystrophy syndrome. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, June 1999 [abstract 21].
9. Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus. Lancet 1999, 353:2893-2899.
10. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001, 15:1389-1398.
11. Rozenbaum W, Gharakhanian, Salhi Y, et al. Clinical and laboratory characteristics of lipodystrophy in a French cohort of HIV-infected patients treated with protease inhibitors. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, June 1999 [abstract 12].
12. APROCO Study Group on Metabolic Complications. A cross-sectional study of metabolic disorders and lipodystrophy in HIV-infected patients treated with antiretroviral combination therapy including protease inhibitors (PI) within a phase IV cohort study of PI: APROCO-ANRS EP11. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, June 1999 [abstract 23].
13. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999, 13:1659-1667.
14. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000, 14:F25-F32.
15. Miller JE, Emery S, French M, Baker D, Cooper DA. The Australian prevalence survey of lipodystrophy syndrome. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, January 2000 [abstract 201].
16. Boubaker K, Sudre P, Flepp M, et al. Hyperlactatemia and antiretroviral therapy in the Swiss HIV Cohort Study. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, January 2000 [abstract 57].
17. Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Clin Infect Dis 2000, 31:1482-1487.
18. Galli M, Veglia F, Angarano G, et al. Metabolic and morphological alterations under antiretroviral therapy: preliminary results of Lipodystrophy Italian Multicentre Study (LIMS). AIDS 2000, 14(suppl 4):S54. [Abstract]
19. Heath K, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001, 15:231-240.
20. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001, 357:592-598.
21. Bogner JR, Vielhauer V, Beckmann RA et al. Stavudine versus zidovudine and the development of lipodystrophy. J AIDS 2001, 27:237-244.
22. Lumpkin MM. Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus infection. FDA Public Health Advisory, 11 June 1997.
23. Dube MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia. Lancet 1997, 350:713-734.
24. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired glucose tolerance in HIV-1-infected patients. AIDS 1998, 12:F167-F174.
25. Yarasheski KE, Tebas P, Sigmund C, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immun Defic Syndrom 1999, 21:209-216.
26. Hadigan C, Meigs J, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001, 32:130-139.
27. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Clin Endocrinol Metab 1992, 74:1045-1052.
28. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV protease inhibitor-associated syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet 1998, 351:1881-1883.
29. Lenhard JM, Weiel JE, Paulik MA, et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Res 2000, 47:121-129.
30. Zhang B, MacNaul K, Szalkowski D, Li Z, Berger J, Moller DE. Inhibition of adipocyte differentiation by HIV protease inhibitors. J Clin Endocrinol Metab 1999, 84:4274-4277.
31. 1 acid signaling by the HIV protease inhibitor indinavir. Biochem Pharmacol 2000, 59:1063-1068.
32. Wentworth JM, Burris TP, Chatterjee VKK. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARγ/RXR heterodimer. J Endocrin 2000, 164:R7-R10.
33. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001, 50:1378-1388.
34. Rudich A, Vanounou S, Riesenberg K et al. The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3TC-L1 adipocytes. Diabetes 2001, 50:1425-1431.
35. Dowell P, Flexner C, Kwiterovich PO, Lane MD. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem 2000, 275:41325-41332.
36. Parker RA, Meyers DS, Andrews BA, Flint OP, Durham SK. Effects of nucleoside reverse transcriptase inhibitors and HIV protease inhibitors on adipogenesis and adipocyte metabolism. 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Toronto, September 2000 [abstract O4].
37. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999, 354:1112-1125.
38. Gaou I, Malliti M, Guimont MC, et al. Effects of stavudine on mitochondrial genome and fatty acid oxidation in lean and obese mice. J Pharmacol Exp Ther 2001, 297:516-523.
39. Shikuma C, Hu N, Milne C, et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV infected individuals with peripheral lipoatrophy. AIDS 2001, 15:1801-1809.
40. Walker UA, Bickel M, Lütke-Volksbeck SI, et al. Decrease of mitochondrial DNA content in adipose tissue of HIV-infected patients treated with NRTIs. 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Toronto, September 2000 [abstract O6].
41. Miller J, Carr A, Emery S, Law MG, Grey P, Smith D, Cooper DA. Lipodystrophy following antiretroviral therapy of primary HIV infection. AIDS 2000, 14:2406-2407.
42. Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomised, multicentre, open-label study. AIDS 2001, 15:1811-1822.
43. Saint-Marc T, Touraine J-L. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS 1999, 13:2188-2189.
44. Rietschel P, Hadigan C, Corcoran C, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 2001, 86:504-510.
45. Purnell J, Zambon A, Knopp R, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000, 14:51-57.
46. Distler O, Cooper DA, Deckelbaum RJ, Sturley SL. Hyperlipidemia and inhibitors of HIV protease. Curr Opin Clin Nutr Metab Care 2001, 4:99-103.
47. Mooser V, Carr A. Antiretroviral therapy-associated hyperlipidaemia in HIV disease. Curr Opin Lipidol 2001, 12:313-319.
48. Miserez AR, Barella L, Muller PY, et al. Hyperlipoproteinemia in HIV patients is linked to Sterol-Regulatory Elemnt Binding Protein (SREBP) 1c. Eighth Conference on Retrovirus and Opportunistic Infections. Chicago, February 2001 [abstract 500].
49. Garg A. Lipodystrophies. Am J Med 2000, 108:143-152.
50. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001, 15:F11-F18.
51. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999, 401:73-76.
52. Gavrilova O, Marcus-Samuels B, Graham D, et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 2000, 105: 271-278.
53. Gan SK, Samaras K, Thompson CH, et al. Relationship of visceral and muscle cell lipid with insulin sensitivity in HIV-1-infected men with and without protease inhibitor-related lipodystrophy. Diabetes (in press).
54. Nolte LA, Yarasheski KE, Kawanaka K, Fisher J, Le N, Holloszy J. The HIV protease inhibitor indinavir decreases insulin-and contraction-stimulated glucose transport in skeletal muscle. Diabetes 2001, 50:1397-1401.
55. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000, 275:20251-20254.
56. Schutt M, Meier M, Meyer M, Klein J, Areis SP, Klein HH. The HIV-1 protease inhibitor indinavir impairs insulin signaling in HepG2 hepatoma cells. Diabetologia 2000, 43:1145-1148.
57. Kingslet L, Smit E, Riddler S, et al. Prevalence of lipodystrophy and metabolic abnormalities in the Multicenter AIDS Cohort Study (MACS). Eighth Conference on Retrovirus and Opportunistic Infections. Chicago, February 2001 [abstract 538].
58. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000, 14:37-49.
59. Belloso W, Ivalo S, Perman M, et al. Associated features of lipodystrophy may change significantly with definition criteria. 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, June 2001 [abstract 507].
60. Montaner J. Current controversies in antiretroviral therapy and potential solutions: translating science into action. 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, June 2001 [abstract PL2].
61. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998, 351:1328. [Letter]
62. Behrens G, Schimdt H, Meyer D, et al. Vascular complications associated with HIV protease inhibitors. Lancet 1998, 351:1958. [Letter]
63. Flynn TE, Bricker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med 1999, 131:258. [Letter]
64. Koppel K, Bratt G, Rajs J. Sudden cardiac death in a patient on 2 years of highly active antiretroviral treatment: a case report. AIDS 1999, 13:1993-1994.
65. Grunfeld C. Distribution in lipid metabolism due to HIV infection and its therapy. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1999 [abstract S3].
66. Egger M. Metabolic complications of HAART: need for perspective. 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Toronto, September 2000 [abstract O23].
67. Perry RC, Cushing HE, Deeg MA, Prince MJ. Ritonavir, triglycerides, and pancreatitis. Clin Infect Dis 1999, 28:161-162.
68. Roubenoff R, Weiss L, McDermott A, Heflin T, Clouthier GJ, Wood M, Gorbach S. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS 1999, 13:1373-1375.
69. Miller J, Carr A, Brown D, Cooper DA. A randomised, double-blind study of gemfibrozil (GF) for the treatment of protease inhibitor-associated hypertriglyceridaemia. Eighth Conference on Retrovirus and Opportunistic Infections. Chicago, February 2001 [abstract 205].
70. Henry K, Melroe H, Huebesch J, et al. Atorvastatin and gemfibrozil for protease inhibitor-related lipid abnormalities. Lancet 1998, 352:1031. [Letter]
71. Baldini F, Di Giambenedetto S, Cingolani A, et al. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study. AIDS 2000, 14:1660-1662.
72. Saint-Marc T, Touraine J-L. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 1999, 13:1000-1002.
73. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000, 284:472-477.
74. Engelson ES, Glesby M, Sheikhan J, et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection: interim analysis. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, June 1999 [abstract 6].
75. Mauss S, Wolf E, Jaeger H. Reversal of protease inhibitor-related visceral abdominal fat accumulation with recombinant human growth hormone. Ann Intern Med 1999, 131:313-314.
76. Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 1999, 13:2099-2103.
77. Ponce-de-Leon S, Iglesias M, Ceballos J, Ostrosky-Zeichner L. Liposuction for protease-inhibitor-associated lipodystrophy. Lancet 1999, 353:1244. [Letter]
78. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999, 13:805-810.
79. Martinez E, Garcia-Viejo MA, Blanco JL, et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 2000, 31:1266-1273.
80. Walli R, Huster K, Bogner JR, et al. Switching from protease inhibitors to abacavir improves insulin sensitivity and fasting lipids - 12 month follow-up. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 672].
81. Ruiz L, Negredo E, Domingo P, et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy. J AIDS 2001, 27:229-236.